Recruiting

WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt

The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).

ClinicalTrials.gov IDNCT05183230

PhaseNA

Enrollment115

SponsorWeill Medical College of Cornell University

Age50 Years

SexALL

I'm interested View official listing

Conditions studied

Suicide, Attempted, Suicidal Ideation, Depression

About this study

Interventions

Behavioral: WellPATH-PREVENT — WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
Behavioral: Optimized WellPATH-PREVENT — The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.

Primary outcomes

Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61 (Study Entry, Week 6, Week 12)
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Self-Reported Affect - R61 (Study Entry, Week 6, Week 12)
Change in Self-Reported Affect - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R61 (Study Entry, Week 6, Week 12)
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Client Satisfaction with Treatment (CSQ) - R61 (Week 6, Week 12)
Change in Client Satisfaction with Treatment (CSQ) - R33 (Week 6, Week 12, Week 24)

Eligibility information

Inclusion Criteria: * 50-90 years old * Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia * Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts." * We will also include patients on psychotropics and on after-care community psychotherapy. Exclusion Criteria: * Current diagnosis of Psychotic Disorders; Diagnosis of Dementia * Cognitive Impairment (MMSE ≤ 24) * Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry * Aphasia, sensory problems, and/or inability to speak English.

Study locations

New York Presbyterian Hospital/Weill Cornell Medicine, New York, New York 10065 United States
Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York 10605 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.